A Phase 3 interventional study of dimethyl fumarate and Placebo in Multiple Sclerosis, Secondary Progressive, sponsored by Biogen. Terminated at 18 sites in 6 countries. Open to participants aged 18 Years to 58 Years. Per ClinicalTrials.gov, last updated 2017-04-26.
Sponsored by Biogen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States — 25 open to participants now, 38 under way, 9 of them phase 3. Multiple Sclerosis, Chronic Progressive · United States.
Among the 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States, this one is the 45th largest by enrollment of the 85 interventional ones that give a count, is one of 5 that started in 2015, is one of 20 in phase 3, and was the 31st registered.
245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.
Browse Multiple Sclerosis, Chronic Progressive studies →25 of the 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States are open now. Recruiting first, the newest first:
University of Iowa · Sites in United States
Ages 45–70
Sundance Biosciences, Inc. · Sites in United States
Ages 18–70
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
Zenas BioPharma (USA), LLC · Sites in United States, Australia, Bulgaria and 15 more countries
Ages 18–60
Zenas BioPharma (USA), LLC · Sites in United States, Australia, Belgium and 17 more countries
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.
This study: 18 Years to 58 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 32 · Phase 3 22 · Phase 4 1
First in 2002; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is close to the median of 54 across 190 interventional studies indexed under Multiple Sclerosis, Chronic Progressive.
Median enrollment 59 across the 85 interventional studies, 125 across the 20 observational. Of the 62 that completed or were terminated, 28 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 105 have an industry lead sponsor. The 10 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Biogen has 5 studies filed under Multiple Sclerosis, Chronic Progressive — fewer than ten, so there is no comparison to draw.
10 of the studies in Multiple Sclerosis, Chronic Progressive with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07355387University of Illinois at ChicagoHome Based Functional Balance Intervention for Multiple Sclerosis | 2026-11-24 |
| NCT03109288National Institute of Allergy and Infectious Diseases (NIAID)Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) | 2027-01-01 |
| NCT07270120Ohio State UniversitySenolytics for Secondary Progressive MS | 2027-01-15 |
| NCT05122559Emmanuelle Waubant, MD PhDNeuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis | 2027-02 |
| NCT06384976Kyverna TherapeuticsKYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis | 2027-04 |
Add all 10 to your calendar (.ics) → With an account.
Among the 105 studies in Multiple Sclerosis, Chronic Progressive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to investigate whether treatment with BG00012 (dimethyl fumarate) compared with placebo slows the accumulation of disability not related to relapses in participants with secondary progressive multiple sclerosis (SPMS). The secondary objective of the study is to assess the effect of BG00012 compared with placebo on patient-reported outcomes, brain atrophy, and cognitive function.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/Exclusion criteria may apply
BG00012 120 mg (1 BG00012 120 mg capsule + 1 matching placebo capsule) orally twice daily (BID) for 1 week, followed by BG00012 240 mg orally BID thereafter.
Drug: dimethyl fumarate · Other: Placebo
BG00012 120 mg capsule orally once a day supplemented with matching placebo capsules for the first 4 weeks of treatment, as an additional blinding measure. Matched placebo capsules only thereafter.
Drug: dimethyl fumarate · Other: Placebo
capsule
Also known as: DMF, BG00012, Tecfidera
matched placebo capsule
Time to Disability Progression Independent of Relapse
Time to onset of confirmed progression of disability is defined as 1 or more of the following criteria, confirmed at ≥ 6 months after start of treatment and at Week 108 using 1 or more of the following assessments: Expanded Disability Status Scale (EDSS) score increased from Baseline of ≥ 1 point if baseline EDSS ≤ 5.5, or ≥ 0.5 point if Baseline EDSS ≥ 6.0; Timed 25-Foot Walk (T25FW) ≥ 20% increase from Baseline in the time taken for the 25-foot walk; worsening on the 9-Hole Peg Test (9HPT; ≥ 20% increase from Baseline in the time taken for the 9HPT, confirmed in the same hand). The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs.
Time frame: Up to 108 weeks
Change From Baseline to 2 Years on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12)
MSWS-12 is a participant self-assessment of walking limitations due to multiple sclerosis (MS) during the past 2 weeks. It contains 12 items that measure the impact of MS on walking. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater negative impact on walking.
Time frame: Baseline, 2 years
Change From Baseline to Week 108 in ABILHAND Questionnaire Score
The ABILHAND Questionnaire measures the participant's perceived difficulty in performing everyday manual activities in the last 3 months. Participants fill in the 56-item questionnaire by estimating their own difficulty or ease in performing each of the 56 activities. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater impact on manual ability.
Time frame: Baseline, Week 108
Percentage Change From Baseline to Week 108 in Whole Brain Volume
Whole brain volume is measured by magnetic resonance imaging (MRI).
Time frame: Baseline, Week 108
Change From Baseline to Week 108 in Cognitive Function as Measured by the Symbol Digit Modalities Test (SDMT)
The SDMT measures the time to pair abstract geometric symbols with specific numbers. The score is the number of correctly coded items from 0-110 in 90 seconds. A higher score indicates a better outcome.
Time frame: Baseline, Week 108
| Milestone | Placebo | Tecfidera 240 mg BID |
|---|---|---|
| Started | 30 | 28 |
| Completed | 0 | 0 |
| Not completed | 30 | 28 |
| Withdrew: Sponsor decision to stop study early | 30 | 25 |
| Withdrew: Consent withdrawn | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 |
Time to onset of confirmed progression of disability is defined as 1 or more of the following criteria, confirmed at ≥ 6 months after start of treatment and at Week 108 using 1 or more of the following assessments: Expanded Disability Status Scale (EDSS) score increased from Baseline of ≥ 1 point if baseline EDSS ≤ 5.5, or ≥ 0.5 point if Baseline EDSS ≥ 6.0; Timed 25-Foot Walk (T25FW) ≥ 20% increase from Baseline in the time taken for the 25-foot walk; worsening on the 9-Hole Peg Test (9HPT; ≥ 20% increase from Baseline in the time taken for the 9HPT, confirmed in the same hand). The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. The T25FW is a quantitative mobility and leg function performance test where the participant is timed while walking for 25 feet. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs.
No measurements were reported for this outcome.
MSWS-12 is a participant self-assessment of walking limitations due to multiple sclerosis (MS) during the past 2 weeks. It contains 12 items that measure the impact of MS on walking. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater negative impact on walking.
No measurements were reported for this outcome.
The ABILHAND Questionnaire measures the participant's perceived difficulty in performing everyday manual activities in the last 3 months. Participants fill in the 56-item questionnaire by estimating their own difficulty or ease in performing each of the 56 activities. Items are summed to generate a total score and transformed to a scale with a range of 0 to 100, where high scores indicate greater impact on manual ability.
No measurements were reported for this outcome.
Whole brain volume is measured by magnetic resonance imaging (MRI).
No measurements were reported for this outcome.
The SDMT measures the time to pair abstract geometric symbols with specific numbers. The score is the number of correctly coded items from 0-110 in 90 seconds. A higher score indicates a better outcome.
No measurements were reported for this outcome.
Collected over Up to approximately 24 weeks (overall mean time on study of 14.34, with an overall mean time on study treatment of 9.58 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/30 (0%) | 9/30 (30%) |
| Tecfidera 240 mg BID | — | 5/28 (17.9%) | 9/28 (32.1%) |
| Event | Placebo | Tecfidera 240 mg BID |
|---|---|---|
| EnteritisGastrointestinal disorders | 0/30 | 1/28 |
| FallInjury, poisoning and procedural complications | 0/30 | 1/28 |
| Femur fractureInjury, poisoning and procedural complications | 0/30 | 1/28 |
| Multiple sclerosis relapseNervous system disorders | 0/30 | 1/28 |
| Trigeminal neuralgiaNervous system disorders | 0/30 | 1/28 |
| Calculus uretericRenal and urinary disorders | 0/30 | 1/28 |
| NephrolithiasisRenal and urinary disorders | 0/30 | 1/28 |
| Renal colicRenal and urinary disorders | 0/30 | 1/28 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/30 | 1/28 |
| Event | Placebo | Tecfidera 240 mg BID |
|---|---|---|
| FlushingVascular disorders | 5/30 | 5/28 |
| Urinary tract infectionInfections and infestations | 3/30 | 2/28 |
| DiarrhoeaGastrointestinal disorders | 0/30 | 2/28 |
| NauseaGastrointestinal disorders | 0/30 | 2/28 |
| VomitingGastrointestinal disorders | 0/30 | 2/28 |
| Multiple sclerosis relapseNervous system disorders | 0/30 | 2/28 |
| Upper respiratory tract infectionInfections and infestations | 2/30 | 0/28 |
| Age, Continuous(years) | Placebo | Tecfidera 240 mg BID | Total |
|---|---|---|---|
| Mean | 50.7 ± 6.67 | 49.6 ± 8.05 | 50.2 ± 7.33 |
| Age, Customized(participants) | Placebo | Tecfidera 240 mg BID | Total |
|---|---|---|---|
| < 20 years | 0 | 0 | 0 |
| 20 to 29 years | 0 | 0 | 0 |
| 30 to 39 years | 1 | 4 | 5 |
| 40 to 49 years | 10 | 8 | 18 |
| >= 50 years | 19 | 16 | 35 |
| Sex: Female, Male(Participants) | Placebo | Tecfidera 240 mg BID | Total |
|---|---|---|---|
| Female | 19 | 17 | 36 |
| Male | 11 | 11 | 22 |
The record gives a start of May 2015, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dimethyl Fumarate
Multiple Sclerosis, Chronic Progressive →